Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

Exclusion Criteria

• •Objectively documented deep vein thrombosis or pulmonary embolism
• •Patients in whom there is very high suspicion for pulmonary embolism and are on full-dose anticoagulation as per the treating physician
• •Platelets \<30,000 not due to disseminated intravascular coagulation (DIC), based on the International Society of Thrombosis and Haemostasis (ISTH) criteria and American Society of Hematology (ASH) Frequently Asked Questions
• •Active bleeding that poses a contraindication to therapeutic anticoagulation in the opinion of the investigator.
• •History of bleeding diathesis (e.g., hemophilia, severe von Willebrand disease, severe thrombocytopathy)
• •History of intracranial hemorrhage in the last 90 days
• •History of ischemic stroke in the past 2 weeks
• •Major neurosurgical procedure in the past 30 days
• •Cardiothoracic surgery in the past 30 days
• •Intra-abdominal surgery in the past 30 days
• •Intracranial malignancy
• •Patients who require therapeutic anticoagulation for other reasons like atrial fibrillation, deep venous thrombosis, pulmonary embolism, or antiphospholipid syndrome.